Parkinson’s disease tagged posts

n-acetylcysteine (NAC), with strong antioxidant effects, shows potential benefit as part of the management for patients with Parkinson’s disease. Combining clinical evaluations of a patient’s mental and physical abilities with brain imaging studies that tracked the levels of dopamine, the lack of which is thought to cause Parkinson’s, doctors from the Depts of Integrative Medicine, Neurology, and Radiology, at Thomas Jefferson University showed that patients receiving NAC improved on both measures.

Current treatments for Parkinson’s disease are generally limited to temporarily replacing dopamine in the brain as well as some...

Read More

For decades, scientists have fiercely debated whether rapid eye movement (REM) sleep – the phase where dreams appear – is directly involved in memory formation. Now researchers provide evidence that REM sleep does, indeed, play this role – at least in mice. “We already knew that newly acquired information is stored into different types of memories, spatial or emotional, before being consolidated or integrated,” says Sylvain Williams, a researcher and professor of psychiatry at McGill.

“How the brain performs this process has remained unclear – until now...

Read More

Cornell researchers have discovered a way to penetrate the blood brain barrier (BBB) that may soon permit delivery of drugs directly into the brain to treat disorders such as Alzheimer’s disease and chemotherapy-resistant cancers. The BBB is a layer of endothelial cells that selectively allow entry of molecules needed for brain function, such as amino acids, oxygen, glucose and water, while keeping others out. An FDA-approved drug, Lexiscan activates adenosine receptors – that are expressed on these BBB cells.

“We can open the BBB for a brief window of time, lo...

Read More

Chemists have identified the complex chemical structure of the protein that stacks together to form fibrils in the brains of Parkinson’s disease patients. Thus researchers can identify specific targets for diagnosis and treatment. In Parkinson’s, the protein alpha-synuclein forms long fibrils that disrupt brain activity. This is similar to the beta-amyloid fibrils that form in Alzheimer’s disease patients. However, while the beta-amyloid structure is known, the alpha-synuclein structure has eluded researchers as a result of its complexity, its insolubility and the difficulty of characterizing one protein within a fibril.

“This is the first structure of the full-length fibril protein, which is now well established to be important for the patho...

Read More